Author name: Leonardo Arias

Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges created by the technology.

OrganOx has the potential to capture a greater share in the liver transplant market, where it competes with TransMedics Group, Needham analyst Mike Matson wrote.

The Thursday ruling allows the National Institutes of Health to cut nearly $800 million of research funds for studies like HIV prevention.

The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.

LB Pharma will test the IPO market to seek funding for a Phase III-ready schizophrenia asset.

On Friday, a Maryland district judge paused the creation of a fine for individuals who automatically reenroll in ACA plans, a policy making it harder for people to receive subsidies and other key elements of a controversial final rule from July.

The company has lost 57 unique acute care customers in the past three years, 12 of which are larger health systems with more than 1,000 beds, according to a report by Klas Research.

From M&A to MDUFA and the developing market in renal denervation, MedTech Dive covers the key issues for the industry to watch in the final months of the year.

Top roles at Intuitive, Boston Scientific, Dexcom and others changed hands this year. Read MedTech Dive’s roundup for all the details.

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare disease called Alagille syndrome.